2423943-37-5

2423943-37-5 structure

Name: Bamlanivimab
Chemical Name: Bamlanivimab
CAS Number: 2423943-37-5
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2023-01-16 10:13:19
Modify Date: 2024-01-10 22:45:42
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab[1].

Name	Bamlanivimab

Description	Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
Target	SARS-CoV-2[1]
References	[1]. Benschop RJ, et al. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Sci Transl Med. 2022 Jul 27;14(655):eabn3041.

No Any Chemical & Physical Properties